ICH E2A Definitions and Standards for Expedited Reporting Flashcards

University of Cali slideshow

1
Q

Define Adverse Event

A

An untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a casual relationship with this treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

An ____________ can be any unfavorable and unintended sign (e.g. an abnormal lab finding), symptom, or disease temporarily associated with the use of a drug, without any judgment about causality or relationship to the drug.

A

adverse event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define Serious Adverse Event

A

death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hospitalization

A

Admission to the hospital for longer than 24 hours or prolongation of hospital stay due to adverse event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Congenital Anomaly

A

Exposure to a medical product prior to conception or during pregnancy resulting in an adverse outcome in the child.

Example: Thalidomide - babies born with deformed arms and legs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Important medical events that may not result in death, be life threatening, or require hospitalization may be considered a ____________________ when based upon appropriate medical judgment (they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition)

A

serious adverse event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Toxicities from the study drug are consdiered expected (vs unexpected) if found in…

A
  • safety info on approved products is reflected in product labeling (package insert)
  • up to date safety info on the products under investigation is found in the Investigator’s Brochure
  • from these sources the protocol and ICF is written to explain and describe what risks we currently expect from this study drug
  • safety profile of other drugs in this same class
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define an Unexpected Adverse Event

A

An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required, available, is not consistent with the risk info described in the general investigational plan or elsewhere in the current application, as amended.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The following are examples of ________________

  • hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure only referred to elevated hepatic enzymes or helpatitis
  • cerbral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the IB only listed cerebral vascular accidents
A

Unexpected Adverse Events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Severity vs Serious

A

Severity: Refers to the intensity of the event. Is expressed in ‘grades’ of severity. Event itself may be minor (severe headache)

Serious: events that threaten subjects life or functioning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

It is the reponsibility of the ___________ to concur with all intensity assessments added to the database for the events identified in the subject

A

Principal Investigator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Adverse Drug Reaction

A

All noxious and unintended responses to medicinal product related to any dose should be considered adverse drug reactions.

“responses to medicinal products” means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Unexpected Adverse Drug Reaction

A

An adverse reaction which the nature or severity of which is not consistent with the applicable product information (e.g. Investigator’s Brochure for an unapproved investigational medicinal product)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

life threatening

A

RISK OF DEATH AT THE TIME OF THE EVENT
-It does not refer to an event which hypothetically might have caused death if it were more severe.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Standards for Expedited Reporting: AE must be

A
  1. Serious
  2. Unexpected
  3. Related (reasonable suspected causal relationship to IP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Reporting Timeframes for Fatal or Life-Threatening Unexpected ADR’s

A

-REGULATORY AUTHORITIES should be notified by SPONSOR in writing soon as possible but no later than 7 calendar days after first knowledge by the sponsor
-followed by as complete report within 8 additional calendar days

17
Q

Reporting Time Frame for All Other Serious, Unexpected ADRs

A

as soon as possible but no later than 15 calendar days after first knowledge by the SPONSOR to REGULATORY AUTHORITIES

18
Q

Breaking the blind
1) When should it occur?
2) Who should do it?

A

1) when a serious adverse reaction is judged reportable on an expedited basis
2) only broken for that specific patient by the sponsor

19
Q

What is the timeline for reporting serious, Fatal or Life-Threatening Unexpected ADRs ?

A

-7 calendar days from the day it became known for the first time
-Additional 8 days for follow up report

Sponsor reports to regulatory authorities

20
Q

What is the timeline for all other Serious, Unexpected ADRs?

A

15 calendar days from the day it became known for the first time

Sponsor reports to regulatory authorities

21
Q

What does severity refer to?

A

the intensity of a condition

like a mild, moderate, or severe headache

A severe headache can be considered NOT serious when it does not comply with the conditions of resulting in death, being life threatening, requiring inpatient hospitalization or prolongation of existing hospitalization, resulting in persistant or significant disability/incapacity or a congenital anomaly/birth defect

22
Q

Minimum Criteria for Reporting

A

Identifiable patient, name of IP, identifiable reporting source, event or outcome that is serious and unexpected, reasonable causal relationship to IP

23
Q

Hospitalization

A

Admission to the hospital for longer than 24 hours or prolongation of hhospital stay due to adverse event

24
Q

Disability

A

A substantial disruption of a person’s ability to conduct normal life funtions.

Examples: loss of speech, fatigue so great the subject cannot get out of bed at all, loss of memory, paralysis

25
Q

Congenital Anomaly

A

Exposure to a medical product prior to conception or during pregnancy resulting in an adverse outcome in the child.

Example: Thalidomide - babies born with deformed arms and legs

26
Q

Define an Unexpected Adverse Event

A

An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or seerity that has been observed; or, if an investigator brochure is not required, available, is not consistent with the risk info described in the general investigational plan or elsewhere in the current application, as amended.

27
Q

Severity (vs Serious)

A

Refers to the intesity of the event and can be used with any even without regard to whether or not it meets the federal criteria for “serious”… is expressed in ‘grades’ of severity

28
Q

Investigator safety reporting responsibilities

A

-All serious adverse events (SAEs) should be reported immediately to the sponsor
-Also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

29
Q

Safety Events:

Investigators report to the sponsor: 

A

Any adverse event (AE) determined to be caused by (or probably caused by) the drug

30
Q

Safety Events:

Sponsors report to investigators and and regulatory authorities

A

Any ADR that is both serious and unexpected

Sponsors should also inform investigators of any new observations regarding the drug, especially AEs and safe use concerns

31
Q

Safety Events:

Investigators and sponsors report to the IRB

A

All unanticipated problems (UAPs) involving risks to human subjects or others